BOSTON — Scientists say a revolutionary new device, the size of a matchbox, could be the most effective weapon yet in the fight against obesity.
The vBloc, made by EnteroMedics Inc., provides new hope for the nearly one-third of obese adult Americans in the form of a tiny implant. The Food and Drug Administration approved pacemaker-like device is implanted into the abdomen. It works by sending electrical pulses through the nerve pathway between the brain and the stomach helping patients to feel full. Read More
Biosimilar drugs may curb health care costs
The first biosimilar drug approved for the U.S. market has put the spotlight on how such medications could help employers with their ongoing health care cost battle, while biologic-drug makers are fighting biosimilars in court.
Biosimilars are “closely similar” to biologics, according to the U.S. Food and Drug Administration. Biologics are costly specialty drugs used to treat diseases such as cancer, rheumatoid arthritis and diabetes. Read More
In Massachusetts, biotech firms account for a lot of value but few jobs
When we talk about biotech, we’re usually talking about dollars far more than we’re talking about jobs. But exactly how few jobs we’re talking about may surprise you. It may also help explain why the Massachusetts Life Science Center has struggled to bring about the kind of job growth once hoped for. Read More
Safer sunscreen ingredients waiting approval from FDA
Greater awareness about what’s in everyday products and increased interest in healthy living means there has never been a better time to re-evaluate which sunscreens you use. The ingredients in some common chemical-based sunscreens are known to cause allergic reactions for some people and have been linked to reproductive and behavioral problems in animal studies. But luckily for the sun-safe and health conscious among us, there are lots of widely available all-natural, mineral-based sunscreen formulations that won’t cause any health problems on store shelves these days. Read More
The Rise and Fall of 3 Market Darling Healthcare Stocks
Within the upward trending Healthcare Sector lurks the siren call of the explosive potential of Biotech and Medical Equipment stocks. Investors flock to companies touting new drugs or devices to treat a variety of medical conditions. Unfortunately, that explosive potential is a double-edged sword, as a dramatic rise in share price can later see an equally dramatic fall.
In the last three months three companies once favored by investors and analysts alike have seen share price declines ranging from 12% to 30%. Here are the three stocks and the percentage drop of each:
• Acrux Limited (ACR) -30%
• ResMed Inc. (RMD) -15%
• Sirtex Medical Limited -12%
Roche Receives FDA Approval For Its Cobas KRAS Mutation Test
Roche recently announced that the United States Food and Drug Administration (FDA) has approved its cobas KRAS Mutation Test to be used for diagnostic purposes. This real-time PCR test was developed to find KRAS mutations in tumor samples that are collected from patients with metastatic colorectal cancer (mCRC) and help clinicians to better determine a suitable therapeutic path.
“As more targeted treatment options for cancer patients become available, the importance of identifying the right molecular information to define their disease becomes critical. The cobas® KRAS Mutation Test gives clinicians actionable insights that enable them to make informed decisions about treatment for their patient. With this approval, Roche now offers the most comprehensive companion diagnostic FDA approved portfolio for oncology in the U.S., including tests for BRAF (melanoma), EGFR (lung cancer) and KRAS (mCRC) mutations,” explained Paul Brown, the Head of Roche Molecular Diagnostics. Read More
Driven By Pfizer Inc. And Novartis AG (ADR), Global Breast Cancer Drug Sales Expected To Soar By 2020
Global breast cancer branded drug sales may rise to $20 billion in 2020, compared to $13 billion reported in 2014, as per consensus data compiled by Bloomberg Intelligence, which only takes into account currently approved drugs. Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) accounted for almost 70% of all breast cancer drug sales in 2014, while it is expected that Pfizer Inc. (NYSE:PFE) will be the key growth driver for 24% of sales in 2020 with its star breast cancer drug, Ibrance. New breast cancer drugs from Novartis AG (ADR) (NYSE:NVS) can add another $5 billion to global sales for the disease in 2020. Read More